UA91204C2 - Композиция для преодоления опосредствованной бета-лактамазой резистентности к антибиотикам с использованием ингибитора бета-лактамазы, предназначенная для инъекции - Google Patents

Композиция для преодоления опосредствованной бета-лактамазой резистентности к антибиотикам с использованием ингибитора бета-лактамазы, предназначенная для инъекции

Info

Publication number
UA91204C2
UA91204C2 UAA200707280A UAA200707280A UA91204C2 UA 91204 C2 UA91204 C2 UA 91204C2 UA A200707280 A UAA200707280 A UA A200707280A UA A200707280 A UAA200707280 A UA A200707280A UA 91204 C2 UA91204 C2 UA 91204C2
Authority
UA
Ukraine
Prior art keywords
beta
lactamase
injection
antibiotic resistance
combating
Prior art date
Application number
UAA200707280A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Ману Чаудхарі
Original Assignee
Ману Чаудхарі
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ману Чаудхарі filed Critical Ману Чаудхарі
Publication of UA91204C2 publication Critical patent/UA91204C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
UAA200707280A 2004-12-02 2005-11-28 Композиция для преодоления опосредствованной бета-лактамазой резистентности к антибиотикам с использованием ингибитора бета-лактамазы, предназначенная для инъекции UA91204C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2411DE2004 2004-12-02

Publications (1)

Publication Number Publication Date
UA91204C2 true UA91204C2 (ru) 2010-07-12

Family

ID=35789266

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200707280A UA91204C2 (ru) 2004-12-02 2005-11-28 Композиция для преодоления опосредствованной бета-лактамазой резистентности к антибиотикам с использованием ингибитора бета-лактамазы, предназначенная для инъекции

Country Status (23)

Country Link
US (2) US8273732B2 (enExample)
EP (1) EP1841432B1 (enExample)
JP (1) JP5269415B2 (enExample)
KR (2) KR20070067189A (enExample)
CN (1) CN101060846A (enExample)
AT (1) ATE476981T1 (enExample)
AU (1) AU2005310888B2 (enExample)
BR (1) BRPI0517128A (enExample)
CY (1) CY1110886T1 (enExample)
DE (1) DE602005022939D1 (enExample)
DK (1) DK1841432T3 (enExample)
ES (1) ES2349301T3 (enExample)
HR (1) HRP20100591T1 (enExample)
MX (1) MX2007006540A (enExample)
NZ (1) NZ555075A (enExample)
PL (1) PL1841432T3 (enExample)
PT (1) PT1841432E (enExample)
RS (1) RS51506B (enExample)
RU (1) RU2397768C2 (enExample)
SI (1) SI1841432T1 (enExample)
UA (1) UA91204C2 (enExample)
WO (1) WO2006059344A1 (enExample)
ZA (1) ZA200704394B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030010176A (ko) * 2001-07-25 2003-02-05 이병두 은행 열매 추출물과 호도 열매 추출물을 이용한 천식 치료제
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
JP5639471B2 (ja) * 2008-07-28 2014-12-10 惠三 山口 感染症治療効果増強剤
CN101537009B (zh) * 2009-04-30 2010-09-15 海口奇力制药股份有限公司 注射用头孢曲松钠他唑巴坦钠复方制剂的生产工艺
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
EP3412289A1 (en) * 2011-05-28 2018-12-12 Wockhardt Limited Antibacterial compositions
EP2768503A1 (en) * 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
WO2013042140A2 (en) * 2011-09-23 2013-03-28 Manu Chaudhary Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement
MY169816A (en) 2012-03-26 2019-05-16 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
EP2858636B1 (en) 2012-06-07 2018-09-05 Childrens Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
US20150306076A1 (en) * 2012-09-27 2015-10-29 Cubist Pharmaceuticals, Inc. Tazobactam arginine antibiotic compositions
MX2016010699A (es) 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.
EP3125887A1 (en) * 2014-03-29 2017-02-08 Wockhardt Limited Pharmaceutical compositions comprising cefepime or sulbactam
SG11201509950TA (en) * 2014-04-03 2016-01-28 Kewpie Kabushiki Kaisha Also Trading As Kewpie Corp Injection fluid bag and injection preparation
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
JP6891275B2 (ja) * 2016-11-02 2021-06-18 湘北威爾曼制薬股▲分▼有限公司Ｘｉａｎｇｂｅｉ Ｗｅｌｍａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ セフトリアキソンナトリウムとスルバクタムナトリウムからなる組成物
CN111249284B (zh) * 2016-11-03 2022-10-04 湘北威尔曼制药股份有限公司 治疗淋病奈瑟菌感染的头孢曲松钠舒巴坦钠
RU2665006C1 (ru) * 2017-02-28 2018-08-24 Общество с ограниченной ответственностью "Супербаг Солюшенс" Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения
EP4272831A3 (en) 2018-08-09 2024-02-21 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP4262860A4 (en) 2020-12-17 2025-11-12 Idexx Lab Inc DETECTION AND TREATMENT OF ROCKY MOUNTAIN SPRINKLE FEVER
WO2025165991A1 (en) * 2024-01-31 2025-08-07 The Penn State Research Foundation Biopolymeric anti-antibiotics and methods for making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630510B1 (en) * 1999-10-28 2003-10-07 Merck & Co., Inc. Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
PL1468697T3 (pl) * 2003-04-14 2008-05-30 Wyeth Corp Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań

Also Published As

Publication number Publication date
DE602005022939D1 (de) 2010-09-23
RU2007124325A (ru) 2009-01-10
WO2006059344A1 (en) 2006-06-08
KR20090101514A (ko) 2009-09-28
ZA200704394B (en) 2008-09-25
US8273732B2 (en) 2012-09-25
PT1841432E (pt) 2010-10-25
JP2008521884A (ja) 2008-06-26
HRP20100591T1 (hr) 2010-12-31
SI1841432T1 (sl) 2011-02-28
WO2006059344B1 (en) 2006-11-02
EP1841432A1 (en) 2007-10-10
KR20070067189A (ko) 2007-06-27
CN101060846A (zh) 2007-10-24
US9012442B2 (en) 2015-04-21
DK1841432T3 (da) 2010-12-06
BRPI0517128A (pt) 2008-09-30
RU2397768C2 (ru) 2010-08-27
ES2349301T3 (es) 2010-12-29
EP1841432B1 (en) 2010-08-11
US20100160277A1 (en) 2010-06-24
PL1841432T3 (pl) 2011-01-31
KR101244362B1 (ko) 2013-03-18
JP5269415B2 (ja) 2013-08-21
NZ555075A (en) 2011-02-25
US20130023512A1 (en) 2013-01-24
AU2005310888A1 (en) 2006-06-08
RS51506B (sr) 2011-06-30
CY1110886T1 (el) 2015-06-10
ATE476981T1 (de) 2010-08-15
AU2005310888B2 (en) 2011-01-06
MX2007006540A (es) 2008-01-31

Similar Documents

Publication Publication Date Title
HRP20120004T1 (en) Dipeptidyl peptidase inhibitors for treating diabetes
GEP20135791B (en) Use of dipeptidyl peptidase inhibitors
WO2008063671A3 (en) Heterobicyclic metalloprotease inhibitors
WO2007139856A3 (en) Heterobicyclic metalloprotease inhibitors
WO2004037181A3 (en) Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
WO2007139860A3 (en) Heterobicylic metalloprotease inhibitors
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
SG154433A1 (en) Phthalazine derivatives as parp inhibitors
DE60301491D1 (en) Acc-hemmer
WO2005112646A3 (en) Treatment of diet-related conditions using phospholipase-a2 inhibitors comprising indoles and related compounds
MX2009009541A (es) Inhibidores de metaloproteasa que contienen una porcion heterociclica.
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
PA8620301A1 (es) Inhibidores heterociclil amino de 11-beta-hidrosiesteroide deshidrogenasa tipo 1
BRPI0913457A2 (pt) "composto, composição farmacêutica, e, uso do composto"
UA91027C2 (ru) ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕЖДУ MDM2 И р53
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
IL198979A (en) Enzyme inhibitors diacylglycerol o-acetyltransferase type 1
WO2005005389A3 (en) Malonamide derivatives
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
ZA200806778B (en) N-Hydroxyacrylamide compounds
IL174665A0 (en) Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same
DK1841432T3 (da) Sammensætninger til bekæmpelse af Beta-lactamase-medieret antibiotisk resistens ved anvendelse af Beta-lactamase-hæmmere, der er anvendelige til injektion
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
WO2005041904A3 (en) Inhibitors of coronavirus protease and methods of use thereof